Results 91 to 100 of about 2,249 (191)

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, Volume 53, Issue 3, Page 454-460, March 2026.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review

Experimental Dermatology, Volume 35, Issue 3, March 2026.
ABSTRACT The human gut microbiota is involved in immune regulation, metabolism, and skin homeostasis. In recent years, gut microbiota alterations have been linked with several inflammatory skin disorders, such as atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS).
Andrea Malgesini, Matteo Domenico Marsiglia, Elisa Borghi, Angelo V. Marzano, Gianluca Nazzaro   +4 more
wiley   +1 more source

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme [PDF]

, 2015
BACKGROUND : The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2).
Bachert, Claus, Beeh, Kai M, Bille, Joachim, Buhl, Roland, Garn, Holger, Hohlfeld, Jens M, Homburg, Ursula, Ignatenko, Stanislav, Kappeler, Dominik, Kirsten, Anne-Marie, Korn, Stephanie, Kornmann, Oliver, Krug, Norbert, Renz, Harald, Renz, Jonas, Rogon, Cordelia, Timmer, Wolfgang, Turowska, Agnieszka, Werfel, Thomas, Zeitvogel, Jana, Zhang, Nan   +20 more
core   +2 more sources

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Journal of Dermatological Treatment
Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after ...
Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J. Nickoloff, Chitra R. Natalie, Gaia Gallo, Angela Okragly, Eric Wolf, Chenjia Xu, Brian A. Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson   +14 more
doaj   +1 more source

Lebrikizumab may benefit a subset of patients with asthma [PDF]

Thorax, 2011
Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling. In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that ...
openaire   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 415-422, March 2026.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B‐Like 2 (PLBL2) Captured From a Monoclonal Antibody

Biotechnology and Bioengineering, Volume 123, Issue 2, Page 406-419, February 2026.
A platform approach to the affinity capture and enrichment of host cell proteins to enable their subsequent deep characterization and elucidation of variants or proteoforms (e.g., molecular size variants, charge variants, glycoforms, etc.). ABSTRACT Removing host cell proteins (HCPs) during biotherapeutic manufacturing is essential to ensure patient ...
Michael E. Dolan, Lei (Leo) Wang, Alexander Tedeschi, Yan Wang, Christopher Barton, Sheldon F. Oppenheim, Zhaohui Sunny Zhou   +6 more
wiley   +1 more source

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) affects multiple areas of the body, some of which may be more refractory to treatment. We evaluated improvements in the Eczema Area and Severity Index (EASI) by body region and clinical signs for each body region in ...
Eric L. Simpson, Marjolein de Bruin-Weller, H. Chih-ho Hong, Delphine Staumont-Sallé, Andrew Blauvelt, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, Zhuqing Liu, Helena Agell, Jonathan I. Silverberg   +14 more
doaj   +1 more source

Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells [PDF]

, 2016
DPP4 mRNA showed significant correlation with iNOS mRNA in the freshly isolated BECs from snBA.
Akihiro Takemasa, Kazuyuki Chibana, Ryo Arai, Taichi Shiobara, Taiji Watanabe, Yasuo Shimizu, Yoshiki Ishii, Yukiko Horigane, Yumeko Hayashi, Yusuke Nakamura   +9 more
core   +4 more sources

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and ...
Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong   +8 more
doaj   +1 more source